BRAF and skin squamous cell carcinoma: Squamoproliferative lesions such as actinic keratoses and CSCC are most commonly seen with BRAF inhibitors such as vemurafenib, dabrafenib, and encorafenib, which can be used as monotherapies for patients with metastatic melanoma harboring BRAF V600E mutations.